{"id":553638,"date":"2021-07-20T16:08:02","date_gmt":"2021-07-20T16:08:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=553638"},"modified":"2021-07-20T16:08:02","modified_gmt":"2021-07-20T16:08:02","slug":"gastroesophageal-adenocarcinoma-market-size-and-trends-analysis-clinical-and-commercial-assessment-of-the-pipeline-therapies-leading-companies-and-epidemiology-forecast","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/gastroesophageal-adenocarcinoma-market-size-and-trends-analysis-clinical-and-commercial-assessment-of-the-pipeline-therapies-leading-companies-and-epidemiology-forecast_553638.html","title":{"rendered":"Gastroesophageal Adenocarcinoma Market Size and Trends Analysis, Clinical and Commercial Assessment of the Pipeline Therapies, Leading Companies, and Epidemiology Forecast"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Gastroesophageal Adenocarcinoma Market Size and Trends Analysis, Clinical and Commercial Assessment of the Pipeline Therapies, Leading Companies, and Epidemiology Forecast\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Gastroesophageal Adenocarcinoma Market Size and Trends Analysis, Clinical and Commercial Assessment of the Pipeline Therapies, Leading Companies, and Epidemiology Forecast\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Gastroesophageal Adenocarcinoma Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Gastroesophageal Adenocarcinoma Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\">The <strong>Gastroesophageal Adenocarcinoma Market Research Report<\/strong> covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Gastroesophageal Adenocarcinoma market Size from 2017 to 2030 segmented by seven major markets.&nbsp;<\/p>\n<p style=\"text-align: justify;\">The report provides a detailed current <strong>Gastroesophageal Adenocarcinoma treatment practice\/algorithm<\/strong>, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.&nbsp;<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Gastroesophageal Adenocarcinoma Market \" src=\"https:\/\/www.abnewswire.com\/uploads\/174e6f31b220de034382863055b5fdf4.jpg\" alt=\"Gastroesophageal Adenocarcinoma Market \" \/><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Gastroesophageal junction adenocarcinoma<\/strong>&nbsp;begins in the glandular cells located near the GE junction and has also been referred to as &lsquo;esophagogastric junction adenocarcinoma&rsquo;. The risk factors of the disease include Gastroesophageal reflux disease and Barrett&#8217;s esophagus and others along with this smoking and tobacco use also increase the risk.<\/p>\n<p style=\"text-align: justify;\">Common symptoms and signs of Gastroesophageal adenocarcinoma include difficulty or pain with swallowing and unintentional weight loss, cough, nausea and vomiting, and others. Treatment of locally advanced GEJ tumors presents a unique challenge because these tumors have generally been approached as either esophageal or gastric.<\/p>\n<p style=\"text-align: justify;\"><strong>Gastroesophageal Adenocarcinoma Market Key Facts<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Population-based studies in several western countries have shown that the incidence of esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma (GEJAC) has rapidly increased; however, the degree of increment of EAC was less than that of the GEJAC (Walther C et. al,2001)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The Surveillance, Epidemiology and End Results (SEER) cancer registry program in the United States demonstrated an approximately 2.5-fold increase in the incidence of GEJAC from 1973 to 1992, from 1.22 cases per 100,000 individuals (1973-1978) to 2.00 cases per 100,000 individuals (1985-1990), with rates stabilizing in the last two decades, with an incidence of 1.94 cases per 100,000 individuals (2003-2008) (Buas MF et. al)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Based on literature review, numbers of adenocarcinomas classified at cardia or in distal esophagus in the Osaka registry of Japan in 1980-93 were 2,151 and 15; while in the registries of 4 regions in France in 1978-92, the respective numbers were 2,203 and 358 (Lambert, n.d.).<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Benefits of Gastroesophageal Adenocarcinoma Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The market report provides an in-depth analysis of <strong>Gastroesophageal Adenocarcinoma Market Size, Share, Trend, and Epidemiology Forecast<\/strong> till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report will help in developing business strategies by understanding the Gastroesophageal Adenocarcinoma Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The market report covers the <strong>Gastroesophageal Adenocarcinoma current treatment practices<\/strong>, emerging drugs, market share of the individual therapies in the seven major markets.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides a detailed assessment of the Gastroesophageal Adenocarcinoma market in terms of market drivers &amp; barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors.&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em><strong>Get FREE sample copy at:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/gastroesophageal-adenocarcinoma-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/gastroesophageal-adenocarcinoma-market<\/a><\/strong><\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Gastroesophageal Adenocarcinoma Market&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted <strong>Gastroesophageal Adenocarcinoma market size and share<\/strong> by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report gives a thorough detail of the <strong>Gastroesophageal Adenocarcinoma market trend<\/strong> of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.<\/p>\n<p style=\"text-align: justify;\"><strong>Gastroesophageal Adenocarcinoma Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The epidemiology section covers insights about the historical and current Gastroesophageal Adenocarcinoma patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Gastroesophageal Adenocarcinoma Epidemiology Subtype Segmentation<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Total incidence of Gastroesophageal Junction Adenocarcinoma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Gender-specific cases of Gastroesophageal Junction Adenocarcinoma&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Biomarker-specific cases of Gastroesophageal Junction Adenocarcinoma<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Gastroesophageal Adenocarcinoma Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the <strong>Gastroesophageal Adenocarcinoma market<\/strong> or expected to get launched in the market during the study period. The analysis covers Gastroesophageal Adenocarcinoma market uptake by drugs; patient uptake by therapies; and sales of each drug.&nbsp;&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Report&rsquo;s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.<\/p>\n<p style=\"text-align: justify;\">The report also covers the <strong>Gastroesophageal Adenocarcinoma Pipeline Development Activities<\/strong> and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><em>Request for Sample @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/gastroesophageal-adenocarcinoma-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">Gastroesophageal Adenocarcinoma Market Outlook<\/a><\/em><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Gastroesophageal Adenocarcinoma Competitive Intelligence Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Gastroesophageal Adenocarcinoma Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Gastroesophageal Adenocarcinoma Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Gastroesophageal Adenocarcinoma Patient Journey<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Gastroesophageal Adenocarcinoma Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Gastroesophageal Adenocarcinoma Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Gastroesophageal Adenocarcinoma Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Key Endpoints of Gastroesophageal Adenocarcinoma Treatment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Gastroesophageal Adenocarcinoma Marketed Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Gastroesophageal Adenocarcinoma Emerging Therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Gastroesophageal Adenocarcinoma Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Attribute Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Gastroesophageal Adenocarcinoma Market Outlook (7 major markets)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Gastroesophageal Adenocarcinoma Access and Reimbursement Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. KOL Views on the Gastroesophageal Adenocarcinoma Market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Gastroesophageal Adenocarcinoma Market Drivers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Gastroesophageal Adenocarcinoma Market Barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">*The table of contents is not exhaustive; the final content may vary.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em><strong>Get FREE sample copy at:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/gastroesophageal-adenocarcinoma-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/gastroesophageal-adenocarcinoma-market<\/a><\/strong><\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Latest Blogs By DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/blog\/cardiac-monitoring-devices-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">Cardiac Monitoring Devices Market Growth<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">As per DelveInsight, the rising incidence of cardiovascular conditions, increasing demand for innovative devices, and technological advancements are expected to drive the growth of the Cardiac Monitoring Devices Market in the coming years. Some of the key companies in the Cardiac Monitoring Devices Market include <em><strong>Medtronic, Boston Scientific, Abbott, GE Healthcare, BIOTRONIK, MicroPort, Nihon Kohden America, SCHILLER, BPL Medical Technologies, ACS Diagnostics, Shenzhen Mindray Bio-Medical Electronics, Lepu Medical Technology, Shree Pacetronix, Metrax GmbH,<\/strong><\/em> among others.<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/blog\/jak-inhibitors-market\/?utm_source=blog&amp;utm_medium=promotion&amp;utm_campaign=blog\">JAK Inhibitors Companies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">As per the DelveInsight, JAK Inhibitors Pipeline is expected to be fuelled by rising prescription demand, however side effects, safety issues, regulatory clearances, and labeling restrictions are the key concerns hampering their growth. Currently, some of the key companies investing in the JAK Inhibitors Portfolio to advance the market share includes <em><strong>Eli Lilly and Company, Astellas Pharma US, Pfizer, Baxter International Inc., Novartis, AbbVie, Sierra Oncology, CTI BioPharma, Incyte,<\/strong><\/em> and others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<br \/><\/strong>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=gastroesophageal-adenocarcinoma-market-size-and-trends-analysis-clinical-and-commercial-assessment-of-the-pipeline-therapies-leading-companies-and-epidemiology-forecast\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=gastroesophageal-adenocarcinoma-market-size-and-trends-analysis-clinical-and-commercial-assessment-of-the-pipeline-therapies-leading-companies-and-epidemiology-forecast\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP DelveInsight&#8217;s &#8220;Gastroesophageal Adenocarcinoma Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Gastroesophageal Adenocarcinoma Market Size and Share in the United States, EU5 &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/gastroesophageal-adenocarcinoma-market-size-and-trends-analysis-clinical-and-commercial-assessment-of-the-pipeline-therapies-leading-companies-and-epidemiology-forecast_553638.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-553638","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/553638","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=553638"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/553638\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=553638"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=553638"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=553638"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}